ReviewMycopathologia2025
A Review of Case Reports of Rare Clinical Yeast Infections in the Last Five Years.
Review in Mycopathologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Managing Breakthrough Fungal Infections in Hematologic Patients: Determinants and Practical Management from a Latin American Perspective on Behalf of INFOCUS LATAM-ISHAM Working Group.Microorganisms · 2026Review
- Urinary tract infection caused by rare yeastFrontiers in immunology · 2026Review
- Not all "Candida" are "Candida": Nakaseomyces glabratus (H.W. Anderson) Sugita & M. Takask. 2022 onychomycosis and the need for rapid diagnostic.FEMS microbiology letters · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The incidence of fungal infections has increased significantly in recent years. In addition to infections caused by common clinical fungal pathogens such as Candida spp., Aspergillus spp. and Trichoderma spp., infections with rare opportunistic fungal pathogens are increasing annually. Infections by rare yeasts are particularly intractable due to difficulties in identification, the absence of clinical breakpoints, and lack of clinical treatment options. The purpose of this review is to provide a comprehensive understanding of clinical cases of infection caused by rare yeasts worldwide in the past five years. Specifically, dozens of case reports of infections caused by rare yeasts, including basidiomycetes and ascomycetes, are summarized. Most infections occurred in newborns and older people. These rare yeasts were mostly isolated from the blood, skin, and other common sites of infection, but isolation from the digestive system, urinary system, and other unexpected anatomical sites was also reported. Although traditional antifungal drugs have good therapeutic effects against most of these rare yeast infections, a small proportion of cases were fatal due to unclear pathogen identification or intrinsic resistance.
Indexed as
Identifiers
40540156What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.